Presence of ear lobe crease may predict intermediate and high-risk patients with acute non-ST elevation acute coronary syndrome


Kahyaoglu M., Gecmen C., Candan Ö., Gucun M., Karaduman A., Guner A., ...Daha Fazla

Journal of Cardiovascular and Thoracic Research, cilt.12, sa.3, ss.172-178, 2020 (ESCI) identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.34172/jcvtr.2020.30
  • Dergi Adı: Journal of Cardiovascular and Thoracic Research
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus
  • Sayfa Sayıları: ss.172-178
  • Anahtar Kelimeler: Ear Lobe Crease, GRACE Score, NSTE-ACS
  • Uşak Üniversitesi Adresli: Hayır

Özet

Introduction: Ear lobe crease (ELC) was first described in 1973 as a physical examination finding indicating significant coronary artery disease (CAD). Several studies have been carried out in relation to this finding, and it has been shown that it is a marker of intima-media thickness, carotid artery disease, and CAD. We aimed to investigate the relationship between earlobe crease, which is a simple physical examination finding, and GRACE score as a risk estimation index in acute coronary syndromes without ST-segment elevation (NSTE-ACS) patients. Methods: 360 patients (mean age 62.2 years, 70% male) were included in our study. Patients were divided into two groups of GRACE scores ≤ 109 and >109, 167 patients were enrolled in group 1, and 193 cases in group 2. Results: The group 2 patients were older, had higher systolic blood pressure (SBP) levels, a higher rate of hypertension, higher glucose levels, lower creatinine clearance levels, higher initial and peak troponin levels, lower hemoglobin levels, lower left ventricular ejection fraction (LVEF) and higher Gensini scores than the patients in group 1. The higher GRACE score group had markedly increased frequencies of ELC compared to the lower GRACE score group (80.8% vs. 24.5%, respectively, P<0.001). Conclusion: The presence of ELC may predict moderate to high risk group of patients with NSTEACS.